PURPOSE: Polymer-coated, dexamethasone (DXM)-releasing stents were tested in order to assess the efficacy of DXM released locally for the prevention of stent restenosis due to intimal hyperplasia. METHODS: Strecker stents coated with a biodegradable membrane containing DXM were implanted percutaneously into the femoral artery in 14 dogs. The contralateral artery received a conventional non-coated stent serving as control. The drugs are eluted by degradation of the carrier membrane. Follow-up intraarterial digital subtraction angiography (DSA) was obtained at 3, 6, 9, 12, and 24 weeks with subsequent autopsy. Specimens for gross and microscopic pathology were obtained and histomorphometry was performed. RESULTS: Four of 14 DXM-coated stents showed thrombotic occlusion within the first 3 weeks; ten DXM-coated stents remained patent. At follow-up DSA, DXM-coated stents showed a significantly wider lumen than the non-coated stents. At morphometry there was less intimal hyperplasia over DXM-coated stents than over non-coated stents (p < 0.05). CONCLUSION: DXM-coated stents reduce neointimal hyperplasia in dogs when compared with non-coated stents.
PURPOSE: Polymer-coated, dexamethasone (DXM)-releasing stents were tested in order to assess the efficacy of DXM released locally for the prevention of stent restenosis due to intimal hyperplasia. METHODS: Strecker stents coated with a biodegradable membrane containing DXM were implanted percutaneously into the femoral artery in 14 dogs. The contralateral artery received a conventional non-coated stent serving as control. The drugs are eluted by degradation of the carrier membrane. Follow-up intraarterial digital subtraction angiography (DSA) was obtained at 3, 6, 9, 12, and 24 weeks with subsequent autopsy. Specimens for gross and microscopic pathology were obtained and histomorphometry was performed. RESULTS: Four of 14 DXM-coated stents showed thrombotic occlusion within the first 3 weeks; ten DXM-coated stents remained patent. At follow-up DSA, DXM-coated stents showed a significantly wider lumen than the non-coated stents. At morphometry there was less intimal hyperplasia over DXM-coated stents than over non-coated stents (p < 0.05). CONCLUSION:DXM-coated stents reduce neointimal hyperplasia in dogs when compared with non-coated stents.
Authors: Ilkka Uurto; Andres Kotsar; Taina Isotalo; Joonas Mikkonen; Paula M Martikainen; Minna Kellomäki; Pertti Törmälä; Teuvo L J Tammela; Martti Talja; Juha-Pekka Salenius Journal: J Mater Sci Mater Med Date: 2007-04-17 Impact factor: 3.896
Authors: Tillmann Cyrus; Huiying Zhang; John S Allen; Todd A Williams; Grace Hu; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza Journal: Arterioscler Thromb Vasc Biol Date: 2008-02-21 Impact factor: 8.311
Authors: Laura J Janke; Chengcheng Liu; Peter Vogel; Jitesh Kawedia; Kelli L Boyd; Amy J Funk; Mary V Relling Journal: Am J Pathol Date: 2013-05-11 Impact factor: 4.307
Authors: Hanna E Auvinen; Yanan Wang; Hans Princen; Johannes A Romijn; Louis M Havekes; Johannes W A Smit; Onno C Meijer; Nienke R Biermasz; Patrick C N Rensen; Alberto M Pereira Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240